Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677774 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL29400785 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL15884802 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL800040 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL29922193 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL6036204 | 0.92 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL874549 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL8361479 | 0.88 | L3MBTL1 (0.48) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 | |
| SCHEMBL8772549 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ANPC1CYP2C19L3MBTL1 | |
| SCHEMBL27355187 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491246-B2 | Combination therapy of arms and natural killer cells | BIOHAVEN THERAPEUTICS LTD. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-07-17 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| CN-113454124-B9 | Combination therapies for ARM and natural killer cells | 克莱奥药品有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113454124-B | Combination therapies for ARM and natural killer cells | 克莱奥药品有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-5565426-A | ANTI-AGGREGATION, INHIBTION OF BLOOD CLOTTING | ADIR ET COMPAGNIE (FR) | 1996-10-15 | — | — | US | disclosed |
| EP-0708765-A4 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO INC (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5525623-A | TRYPTASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-06-11 | — | — | US | disclosed |
| EP-0708765-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0688337-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1995002587-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994020527-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| CN-1070399-A | The amide derivatives oxytocin antagonist that piperizinylcamphorsuoxytocin replaces | MERCK & CO INC (US) | 1993-03-31 | — | — | CN | disclosed |
| EP-0532097-A1 | Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | PTPN1, PTPN5, PTPN2 | SMN1; SMN2 2115/4885RAB9A 862/4885NPC1 2786/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | SMN1; SMN2 2939/4885RAB9A 2714/4885NPC1 2887/4885 |
| US-12491246-B2 | Combination therapy of arms and natural killer cells | PBK, CD47, ICOS | SMN1; SMN2 487/4885RAB9A 2025/4885NPC1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.